MitoQ to Improve Vascular Funciton in Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Coenzyme Q10 Supplementation and Development of Preeclampsia

NCT00300937

Preeclampsia

COMPLETED PHASE3

RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil

NCT00097110

Preeclampsia Eclampsia HELLP Syndrome +1 more

COMPLETED PHASE3

Gene Expression In Pregnancies Complicated by Preeclampsia

NCT00919360

Preeclampsia

TERMINATED

MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study

NCT00763672

Pregnancy Primiparity Hypertension +2 more

COMPLETED NA

Molecular Study of the Maternal-fetal Interface in Preeclampsia.

NCT06232668

Preeclampsia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preeclampsia (PreE) impacts \~10% of pregnancies and has severe outcomes both during and after pregnancy. It is a leading cause of pregnancy-related deaths, and has long term cardiovascular consequences for maternal and child health. Despite advances in our understanding of preeclampsia over the past 50 years, the underlying unifying mechanism causing preeclampsia remains elusive. This critical gap not only encompasses lack of understanding of the pathophysiology, but it also includes a lack of therapeutics for prevention or treatment. Success in this study could translate into a clinical trial that could finally offer a treatment for PreE.

We have recently demonstrated that endothelial function in the human placental microcirculation is impacted by excess reactive oxygen and nitrogen species (ROS, RNS) from the mitochondria (MT), which in preeclampsia, impairs vasodilation. Excess ROS causes decreased nitric oxide (NO) bioavailability, increased lipid peroxidation, uncoupled eNOS, peroxynitrite, and exacerbates MT dysfunction and MT DNA damage via alterations in NO. Microvascular function can be improved by mechanisms that rebalance the oxidative stress response. We have shown that MitoTempol, a MT antioxidant, improves vasodilation. Moreover, we have shown that a major part of the cycle of excessive oxidative stress is caused by MT DNA damage and subsequent activation of toll like receptor 9 (TLR9), and that inhibiting TLR9 prevents this dysfunction. The finding that MT antioxidants given ex-vivo can reverse placental vascular damage after delivery gives promise that treatment of patients during pregnancy could restore vasodilation and allow for safer prolongation of pregnancy.

MitoQ (Mitoquinol Mesylate) is a nutritional supplement, and mitochondrial antioxidant. MitoQ has been extensively studied pre- clinically in cell-culture, and pregnant mouse, rat, and sheep models of PreE or oxidative stress and demonstrated beneficial fetal results. It has been used in clinical trials for heart failure, hepatitis C, Parkinson's, and multiple sclerosis with doses from 10mg to 80mg per day.

Overall Hypothesis: We hypothesize that MitoQ (Mitoquinol Mesylate)-treated preeclampsia patients will have improved brachial artery flow-mediated dilation (FMD) and laser Doppler flowmetry assessments of the cutaneous microvasculature, and that placental endothelial function in micro-vessels and placental pathology will be improved in treated patients. To demonstrate this, we will enroll two pilot human cohorts- one of admitted patients with preeclampsia with severe features who will either continue standard in-patient clinical care or be supplemented daily with MitoQ (Mitoquinol Mesylate) and a second outpatient cohort of patients with preeclampsia without severe features who will received standard outpatient care or be supplemented daily with MitoQ

Aim: Test whether with MitoQ (Mitoquinol Mesylate) treatment in preeclamptic patients improves endothelial function Hypothesis: MitoQ (Mitoquinol Mesylate)-treated patients will have improved brachial artery FMD and laser Doppler flowmetry assessments of the cutaneous microvasculature and placental endothelial function in micro-vessels and placental pathology will be improved in treated patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preeclampsia with Severe Features taking Mitoquinol Mesylate

Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

Group Type EXPERIMENTAL

Mitoquinol Mesylate

Intervention Type DIETARY_SUPPLEMENT

Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

Preeclampsia with Severe Features taking placebo

Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive Placebo daily from enrollment until delivery.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Preeclampsia without Severe Features taking MitoQ

Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

Group Type EXPERIMENTAL

Mitoquinol Mesylate

Intervention Type DIETARY_SUPPLEMENT

Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

Preeclampsia without Severe Features taking placebo

Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive placebo daily from enrollment until delivery.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mitoquinol Mesylate

Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatient Cohort

* pregnant patients with a clinical diagnosis of preeclampsia with severe features
* gestational age between 23+0 and 32+0 weeks' gestation
* singleton pregnancy
* age 18-50 years old
* No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features
* Able to consent and follow a 2-step commend
* English speaking
* Outpatient Cohort

* Pregnant patients with a clinical diagnosis of preeclampsia without severe features
* gestational age between 23+0 and 34+0 weeks' gestation
* singleton pregnancy
* age 18-50 years old
* No indication for immediate delivery
* Planned outpatient management of preeclampsia
* Able to consent and follow a 2-step commend
* English speaking

Exclusion Criteria

* • Unable to stand from chair without physical assistance from another person (able to use assistive device).

* History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
* Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
* History of head trauma or concussion within the past 6 months
* Comorbid neurological disorder
* Peripheral vascular disease
* Diagnosed myocardial infarction or arrhythmia in the previous year
* Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
* Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No